Pure Global
NCT06415175

Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain

Prospective, Observational, Longitudinal Study in Paediatric Patients With AD, Treated With Dupilumab in Spain
Sanofi·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
Dupilumab
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Sanofi
Timeline & enrollment
Phase
N/A
Start date
May 31, 2024
End date
Sep 30, 2027
Enrollment
150 participants
Primary outcome

Demographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Age,Demographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Gender,Characteristic of pediatric patients initiating treatment with dupilumab for Severe AD:Body mass index (BMI),Medical history characteristics of pediatric patients initiating treatment with dupilumab for Severe AD,Medical history of atopic comorbidities,Medical history of non-atopic diseases

Summary

This is a multicentre, prospective, non-interventional study that aims to describe the
 treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in
 Spain: patients' characteristics, disease characteristics, prior treatments for and treatment
 prescription modalities. As well as to document the real-world effectiveness and safety of
 dupilumab during the two years of follow up. No diagnostic or therapeutic intervention
 outside of routine clinical practice will be applied.

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06415175
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06415175 through Pure Global AI's free database. This phase not specified trial is sponsored by Sanofi and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.